Given the wide range of pathways altered by c‐Fos, we compared the 2 and 4 months ORA results with pathways implicated in the development and progression stages of MASLD.[18] Overlapping pathways, such as PPAR and PI3K‐Akt signaling, associated with development and progression stages of MASLD and FosHep are indicated in Venn diagram (Figure 6H). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.